Skip to main navigation Skip to search Skip to main content

A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial

  • Venkataramanan Srinivasan*
  • , Victoria Homer
  • , Darren Barton
  • , Abigail Clutterbuck-James
  • , Siân Jenkins
  • , Claire Potter
  • , Kristian Brock
  • , Ann Logan
  • , Donna Smith
  • , Lars Bruce
  • , Zsuzsanna Nagy
  • , Simon P. Bach
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

124 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science